TLX-66 is under clinical development by Telix Pharmaceuticals and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TLX-66’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TLX-66 is under development for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, juvenile myelomonocytic leukemia (JMML), refractory acute myeloid leukemia and hematopoietic stem cell transplantation. It is administered as intravenous infusion. The drug candidate constitutes murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90. It acts by targeting CD66b expressing cancer cells.
It was also under development for myelodysplasia, multiple myeloma, chronic myeloid leukemia and systemic AL amyloidosis.
Telix Pharmaceuticals overview
Telix Pharmaceuticals (Telix) is a commercial-stage biopharmaceutical company that develops and commercializes radiopharmaceuticals to detect and treat cancer. It offers Illuccix, an imaging agent targeting men with prostate cancer. The company is investigating TLX250-CDx (companion diagnostic) an imaging agent to diagnose renal cancer using positron emission tomography (PET) and TLX250, a radiopharmaceutical therapy against renal cancer. Telix is also evaluating TLX591, an antibody-based therapeutic radiopharmaceutical to treat prostate cancer, TLX101 drug for the treatment of glioblastoma (GBM) and TLX66-CDx and TLX66 programs for bone marrow conditioning. It utilizes molecularly-targeted radiation (MTR) technology, where a radionuclide is attached to a targeting small molecule or antibody that binds to tumor cells and destroys them. The company operates in America, Europe, the Middle East, Africa, and Asia Pacific Regions. Telix is headquartered in Melbourne, Victoria, Australia.
For a complete picture of TLX-66’s drug-specific PTSR and LoA scores, buy the report here.